The goal of this study is to test whether a program reduce stigma will help women living HIV remain in HIV care.
Female; Age 18 years or older;
Registered in the national Medical Information System (MIS) as having received an HIV-positive diagnosis;
Registered in the MIS with injection drug use (IDU) as the probable mode of HIV transmission or with a documented history of injection drug use at any clinical visit.
Does not meet the inclusion criteria;
Unable to provide informed consent;
Unable to provide informed consent due to intoxication, the effects of drug use, or severe psychiatric impairment at the time of consent.
Parallel
Light Inside
BehavioralAdapted intersectional stigma reduction intervention consisting of five facilitator-led, small-group sessions delivered over approximately 2-3 weeks. The intervention uses cognitive-behavioral strategies to reduce HIV- and drug use-related stigma by strengthening adaptive coping, cognitive restructuring, communication skills, social support, and HIV care self-efficacy to improve HIV care engagement and antiretroviral therapy adherence. Participants may also complete an optional individual session with a psychologist facilitator and a support person.
standard of care
BehavioralStandard of Care: Participants will continue to receive standard HIV and substance use care available through their usual healthcare providers. In addition, they will receive a one-time consultation with a social worker, delivered either in person or remotely, to provide support and linkage to available services.
HIV care engagement as assessed by the Number of participants who re-engage in HIV care
Number of participants who re-engage in HIV care, defined as attending at least one HIV clinical care visit within 6 months after study enrollment, as documented in the Medical Information System (MIS).
Antiretroviral therapy (ART) adherence as assessed by the percentage of days covered by dispensed antiretroviral medication
ART adherence, measured as the percentage of days covered by dispensed antiretroviral medication during the 6 months after study enrollment, based on Medical Information System pharmacy records.
Map coordinates are unavailable for these locations. Locations are shown below instead.
UkraineClick on the lead sponsor to view all of their trials.
Johns Hopkins Bloomberg School of Public Health
Lead sponsor
Fogarty International Center of the National Institute of Health
Collaborator
